Renal Cell Carcinoma Protocols

MULTI-001 Nivolumab v11

MULTI-003 Pembrolizumab v11

MULTI-018 Larotrectinib v2

MULTI-019 Entrectinib v2

MULTI-022 Ipilimumab in combination with Nivolumab for CRC and RCC v3

MULTI-027 Cabozantinib (Cabometyx®) v1

RCC-008 Lenvatinib (Kisplyx®) & Everolimus (Afinitor®) v1

RCC-009 Tivozanib v2

RCC-011 Avelumab and axitinib v2

RCC-012 Lenvatinib (Kisplyx®) with pembrolizumab v2
RCC-013 Cabozantinib (Cabometyx®) with nivolumab v1